Yasumura S, Amoscato A, Hirabayashi H, Lin W C, Whiteside T L
Department of Pathology, University of Pittsburgh School of Medicine, PA.
Cancer Immunol Immunother. 1994 Dec;39(6):407-15. doi: 10.1007/BF01534429.
The supernatant of a cell line of squamous cell carcinoma of the head and neck (SCCHN), PCI-50, was previously shown to induce activation, promote proliferation and increase antitumor cytotoxicity of freshly purified human natural killer (NK) cells and CD4+ T lymphocytes [Arch Otolaryngol Head Neck Surg (1994) in press]. This supernatant was found also to promote the growth of a variety of hematopoietic cell lines, including Jurkat, THP-1, K562, NK-92 or Epstein-Barr-virus-transformed B cell lines. The Jurkat cell line was selected as a reporter cell in an 18-h proliferation assay established to measure the growth-promoting activity of PCI-50 supernatant. The presence of soluble tumor-derived factors able to induce proliferation of Jurkat cells was demonstrated in the supernatant produced by several other SCCHN cell lines but not in that produced by a gastric cancer cell line (HR) or renal cell carcinoma line (5117G8). The growth-promoting PCI-50 supernatant was shown to contain 28 +/- 0.5 pg/ml interleukin-6 (IL-6) in vitro but was negative for interferon gamma, IL-1, IL-2, IL-4, tumor necrosis factor alpha, granulocyte/macrophage-colony-stimulating factor and IL-12. The addition of any of these recombinant cytokines to Jurkat cell cultures did not significantly promote growth, while PCI-50 supernatant was consistently growth-stimulatory. This supernatant neither enhanced intracellular Ca2+ concentration in Jurkat cells nor induced up-regulation of activation antigens on the cell surface, although it supported growth of Jurkat cells in the absence of IL-2. The growth-promoting activity in the PCI-50 supernatant was acid-labile at pH 2 for 4 h, heat-resistant at 96 degrees C for 1 h and sensitive to treatments with trypsin and pepsin. Preincubation of the PCI-50 producer cells with tunicamycin or cyclohexamide reduced the level of growth-promoting activity in the supernatant. A partial purification of this activity was achieved using Amicon filtration, chromatography on concanavalin-A-Sepharose and then a hydroxyapatite column and high-pressure liquid chromatography gel filtration. The partially purified glycoprotein had a molecular mass of 50-70 kDa, as determined by gel filtration.
先前的研究表明,头颈部鳞状细胞癌(SCCHN)细胞系PCI-50的上清液可诱导新鲜纯化的人类自然杀伤(NK)细胞和CD4 + T淋巴细胞的激活、促进其增殖并增强抗肿瘤细胞毒性[《耳鼻咽喉头颈外科文献》(1994年)即将发表]。还发现该上清液能促进多种造血细胞系的生长,包括Jurkat、THP-1、K562、NK-92或爱泼斯坦-巴尔病毒转化的B细胞系。在为测量PCI-50上清液的生长促进活性而建立的18小时增殖试验中,选择Jurkat细胞系作为报告细胞。在几种其他SCCHN细胞系产生的上清液中证实存在能够诱导Jurkat细胞增殖的可溶性肿瘤衍生因子,但在胃癌细胞系(HR)或肾癌细胞系(5117G8)产生的上清液中未发现。在体外,具有生长促进作用的PCI-50上清液显示含有28±0.5 pg/ml的白细胞介素-6(IL-6),但干扰素γ、IL-1、IL-2、IL-4、肿瘤坏死因子α、粒细胞/巨噬细胞集落刺激因子和IL-12检测为阴性。将这些重组细胞因子中的任何一种添加到Jurkat细胞培养物中均未显著促进生长,而PCI-50上清液始终具有生长刺激作用。尽管在没有IL-2的情况下它支持Jurkat细胞的生长,但该上清液既未提高Jurkat细胞内的Ca2 +浓度,也未诱导细胞表面激活抗原的上调。PCI-50上清液中的生长促进活性在pH 2下4小时酸不稳定,在96℃下1小时耐热,对胰蛋白酶和胃蛋白酶处理敏感。用衣霉素或环己酰胺对PCI-50产生细胞进行预孵育可降低上清液中生长促进活性的水平。使用Amicon过滤、伴刀豆球蛋白A-琼脂糖层析,然后是羟基磷灰石柱和高压液相色谱凝胶过滤对该活性进行了部分纯化。通过凝胶过滤测定,部分纯化的糖蛋白分子量为50 - 70 kDa。